A review of the clinical pharmacokinetics of polymyxin b

Sean N. Avedissian; Jiajun Liu; Nathaniel J. Rhodes; Andrew Lee; Gwendolyn M. Pais; Alan R. Hauser; Marc H. Scheetz

doi:10.3390/antibiotics8010031

A review of the clinical pharmacokinetics of polymyxin b

Sean N. Avedissian, Jiajun Liu, Nathaniel J. Rhodes, Andrew Lee, Gwendolyn M. Pais, Alan R. Hauser, Marc H. Scheetz

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

Original language	English (US)
Article number	31
Journal	Antibiotics
Volume	8
Issue number	1
DOIs	https://doi.org/10.3390/antibiotics8010031
State	Published - Mar 2019

Keywords

Pharmacokinetics
Polymyxin B

ASJC Scopus subject areas

Microbiology
Biochemistry
Pharmacology, Toxicology and Pharmaceutics(all)
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/antibiotics8010031

Cite this

@article{5fe6580a6a224c54bd9c630607664f16,

title = "A review of the clinical pharmacokinetics of polymyxin b",

abstract = "Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.",

keywords = "Pharmacokinetics, Polymyxin B",

author = "Avedissian, {Sean N.} and Jiajun Liu and Rhodes, {Nathaniel J.} and Andrew Lee and Pais, {Gwendolyn M.} and Hauser, {Alan R.} and Scheetz, {Marc H.}",

year = "2019",

month = mar,

doi = "10.3390/antibiotics8010031",

language = "English (US)",

volume = "8",

journal = "Antibiotics",

issn = "2079-6382",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - A review of the clinical pharmacokinetics of polymyxin b

AU - Avedissian, Sean N.

AU - Liu, Jiajun

AU - Rhodes, Nathaniel J.

AU - Lee, Andrew

AU - Pais, Gwendolyn M.

AU - Hauser, Alan R.

AU - Scheetz, Marc H.

PY - 2019/3

Y1 - 2019/3

N2 - Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

AB - Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious manner to deliver polymyxin B will remain highly important. Recent data have demonstrated that polymyxin B may be less nephrotoxic than colistin. Pharmacokinetically, polymyxin B is primarily eliminated via non-renal pathways, and most do not recommend adjusting the dose for renal impairment. However, some recent studies suggest a weak relationship between polymyxin B clearance and patient creatinine clearance. This review article will describe the clinical pharmacokinetics of polymyxin B and address relevant issues in chemistry and assays available.

KW - Pharmacokinetics

KW - Polymyxin B

UR - http://www.scopus.com/inward/record.url?scp=85064241033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064241033&partnerID=8YFLogxK

U2 - 10.3390/antibiotics8010031

DO - 10.3390/antibiotics8010031

M3 - Article

C2 - 30909507

AN - SCOPUS:85064241033

SN - 2079-6382

VL - 8

JO - Antibiotics

JF - Antibiotics

IS - 1

M1 - 31

ER -

A review of the clinical pharmacokinetics of polymyxin b

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this